The Board of Directors of Active Biotech AB (publ) has issued a notice to the
Annual General Meeting, which is to take place at 5 p.m. on Thursday, May
6, 2010, at the Company's premises at Scheelevägen 22 in Lund, Sweden.
Please see the attached notification, which is being published within short
inSvenska Dagbladet and Post- och Inrikes Tidningar.
Lund, April 6, 2010
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with R&D
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phases
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA
for use in cancer targeted therapy, primarily renal cancer. Further key projects
in clinical development comprise the three orally administered compounds TASQ
for prostate cancer, 57-57 for SLE and RhuDexTM for RA.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication on April 6, 2010, at 8:30 a.m.
[HUG#1400601]
